202
Participants
Start Date
December 31, 2011
Primary Completion Date
June 30, 2014
Study Completion Date
February 29, 2016
Hydromorphone, Injectable
Phase I: 3x daily, up to 500mg per day, for 6 months. Phase II: At 6 months, participants are randomized to either: 1) stay on injectable hydromorphone; 2) switch to oral hydromorphone, for another 6 months.
Diacetylmorphine, injectable
Phase I: 3x daily, up to 1,000mg per day, for 6 months. Phase II: At 6 months, participants are randomized to either: 1) stay on injectable diacetylmorphine; 2) switch to oral diacetylmorphine, for another 6 months.
Hydromorphone, liquid oral
Study Phase II: After 6 months of receiving Hydromorphone injectable , participants will be randomized to stay on injectable hydromorphone or switch to oral hydromorphone, for another six months. Oral = experimental; injectable = active comparator
Diacetylmorphine, liquid oral
Study Phase II: After 6 months of receiving Diacetylmorphine injectable, participants will be randomized to stay on injectable Diacetylmorphine or switch to oral Diacetylmorphine, for another six months. Oral = experimental; injectable = active comparator
SALOME Research Office, Vancouver
Canadian Institutes of Health Research (CIHR)
OTHER_GOV
Providence Healthcare
OTHER
Innerchange Charitable Society
UNKNOWN
University of British Columbia
OTHER